Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct:150:111016.
doi: 10.1016/j.contraception.2025.111016. Epub 2025 Jul 14.

Vaginal contraception with NuvaRing decreases symptoms and uterine features of adenomyosis: A prospective evaluation

Affiliations
Free article
Observational Study

Vaginal contraception with NuvaRing decreases symptoms and uterine features of adenomyosis: A prospective evaluation

Anjeza Xholli et al. Contraception. 2025 Oct.
Free article

Abstract

Objective: We aimed to assess the effects of contraception with NuvaRing on ultrasound signs and symptoms of women with adenomyosis.

Study design: We conducted a prospective self-controlled observational study on women with adenomyosis who required contraception with NuvaRing. Exclusion criteria were actual use or contraindications to hormonal contraception. NuvaRing was administered in a continuous regimen, one ring every 3 weeks without hormone-free intervals, to avoid menses. Adenomyosis, suggested by clinical signs, was confirmed by ultrasonography. Before and after 6 months of NuvaRing, we evaluated uterine volume, direct and indirect ultrasound signs of adenomyosis, and the severity of menstrual, intermenstrual pain, and pain during intercourse, by a 10-cm visual analog scale (VAS).

Result(s): This study included 42 women, 30.0 ± 4.5 years old, with a BMI of 22.8 ± 1.8 kg/m². All were nulliparous except one. Following 6 months of NuvaRing, uterine volume decreased of 14.4 ± 13.5% (p = 0.001). A similar decrease was observed in six women switching from dienogest. Direct ultrasound signs of adenomyosis per patient (total signs/n women) decreased from 0.5 (range 0-3) to 0.08 (range 0-2) (p = 0.003), and indirect signs, from 2.8 (range 1-5) to 1.5 (range 0-5) (p = 0.001). The VAS for menstrual pain decreased from 8.3 ± 1.2 to 3.9 ± 2.5 (p = 0.001), for intermenstrual pain from 6.6 ± 1.4 to 2.9 ± 1.7 (p = 0.001), and for pain during intercourse from 7.0 ± 1.4 to 2.9 ± 1.7 (p = 0.001). The decrease of menstrual pain was significantly associated with the reduction of uterine volume (p = 0.003).

Conclusion(s): Our findings demonstrate that contraception with NuvaRing is a viable contraceptive option for women with adenomyosis.

Implications: In women with adenomyosis contraception with NuvaRing is useful and can be proposed because it reduces the clinical signs and the uterine ultrasound features of adenomyosis.

Keywords: Adenomyosis; Chronic pelvic pain; Contraceptive ring; Dysmenorrhea; Hormonal contraception; Ultrasound.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources